We have developed an innovative tumor tissue profiling platform called the GSProTM (Genetic Spatial Profiling) that transforms patient tumor biopsies into a deep, data-rich analysis for pre-clinical and clinical applications. In combination with our proprietary ONCOMaskTM technology and AI, we are developing a workflow that integrates digital pathology with genetic analysis to create a process that almost exclusively uses digital imaging to predict cancer patient response to drug therapy.
In Jan 2019, we generated our first POC data. Prior to then, we assumed that we had an R and D product. The data showed a clear path in to the clinical market. This has resulted in market pull from both pathology and pharma companies. We are currently in discussions with 2 major pharma groups and a prominent pathology lab in Singapore. Pharma wants to leverage the platform for pre-clinical, clinical and companion diagnostics. We are in late discussions with the path lab to enter in to a fee for service arrangement for clinical assay development.
YOU MIGHT ALSO BE INTERESTED IN
No Offer, Solicitation, Advice, or Recommendation
Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities.